A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer

Xiaoyan Si(Northeast Normal University), Li Zhang(Tianjin Chest Hospital), Liying Cui(Ansteel (China)), Ying Cheng(Jilin Province Tumor Hospital), Jinwan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiang Zhu(Sichuan University), Lei Chen(Zhuzhou Central Hospital), Xiaotong Zhang(Second Affiliated Hospital of Xi'an Jiaotong University), Wei Li(Jilin University), Wei Liu(Hebei Medical University), Jianhua Shi(Linyi People's Hospital), Shucai Zhang(Northeastern University), Lin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Sun(Qingdao University), Yunchao Huang(North China University of Water Resources and Electric Power), Hanping Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Helong Zhang(Shanghai International Studies University)
Therapeutic Advances in Medical Oncology
January 1, 2020
10.1177/1758835920965849
Cited by 15

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k